琥珀酸索利那新对女性膀胱活跃症患者P2X3受体表达的影响

Effect of Solifenacin on P2X3 Receptor Expression in Female Patients with Bladder Active Disease

目的:探讨琥珀酸索利那新对女性膀胱活跃症患者的治疗效果及对膀胱内P2X3受体的表达的影响。方法:选取我院收治的女性膀胱活跃症患者76例,随机分为两组,对照组38例,予托特罗定2 mg,早晚日2次口服;实验组38例,予琥珀酸索利那新5mg,日1次口服,2周为1个疗程,治疗2个疗程。比较两组患者的24 h排尿次数和尿急次数情况,初始尿意容量、最大尿流率、最大膀胱压容量的变化,以及膀胱内P2X3受体的表达情况。结果:治疗前两组患者尿急次数、排尿次数、尿意容量、最大尿流率及最大膀胱压容量无统计学差异,P>0.05;治疗后,患者尿急次数及排尿次数降低,尿意容量、最大尿流率、最大膀胱压容量升高,与对照组比较,实验组改善更明显,差异具有统计学意义,P<0.05。P2X3受体主要表达于膀胱黏膜层和黏膜下层,染色为棕黄色或金黄色;实验组P2X3表达低于正常组,差异具有统计学意义,P<0.05。结论:琥珀酸索利那新能够缓解女性膀胱活跃症患者临床症状,其治疗机制可能为抑制了P2X3受体的表达。

Objective： To investigate the effect of solifenacin on P2X3 receptor expression in female patients with bladder active disease. Methods： 76 cases of female bladder active patients were randomly divided into two groups. 38 cases treated with Todd Luoding 2 mg twice a day. The experimental group of 38 cases was treated with solifenacin 5 mg, once a day, 2 weeks for 1 course, totally 2 courses. The change of 24 h micturition frequency and urgency number, meaning initial urine volume, maximum urine flow rate, maxi- mum bladder pressure capacity, and the expression of P2X3 receptor in bladder were detected and compared between two groups. Results： The number of urgency, urination, urine volume, urinary flow rate and maximum bladder pressure capacity of two groups of patients be- fore treatment had no significant difference, P 〉 0.05. After treatment, the number of urgency and the frequency of urination was reduced, and the urine volume, maximum urine flow rate, maximum bladder pressure capacity was increased in two groups, but more obviously improvement in experimental group than the control group, P 〈0.05. The P2X3 receptor was mainly expressed in bladder mucosa and submucosa, dyed brown or golden yellow. The expression of P2X3 receptor in experimental group was significantly lower than that in control group, P〈 0.05. Conclusions： Solifenacin can alleviate the clinical symptoms of patients with female bladder active patients, the possible treatment mechanism might be the inhibition of P2X3 receptor expression.